| Title |
Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression
|
|---|---|
| Published in |
Psychopharmacology, April 1993
|
| DOI | 10.1007/bf02257418 |
| Pubmed ID | |
| Authors |
G. Gründer, H. Wetzel, E. Hammes, O. Benkert |
| Abstract |
Roxindole is a potent autoreceptor-"selective" dopamine agonist originally developed for the treatment of schizophrenic syndromes. The drug also inhibits 5-HT uptake and has 5-HT1A agonistic actions. In this open clinical trial 12 in-patients suffering from a major depressive episode (DSM-III-R) were treated with roxindole for 28 days in a fixed dosage of 15 mg per day. A reduction of at least 50% in HAMD-17 total scores was observed in 8 out of 12 patients after 4 weeks (mean HAMD-17 reduction of 56% in all patients), while 4 patients did not respond to roxindole treatment. Half of the patients showed a complete psychopathological remission (HAMD-17 < 8). Roxindole's onset of antidepressant action was remarkably rapid. Seven out of eight responders improved within the first 2 weeks of treatment (at least 50% decrease in HAMD-17 total score), and four patients were nearly asymptomatic within 1 week. Our results indicate that roxindole may possess potent antidepressant properties and that its efficacy should be further evaluated by double-blind controlled studies against reference drugs. |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 4% |
| Unknown | 27 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 25% |
| Student > Ph. D. Student | 6 | 21% |
| Lecturer | 2 | 7% |
| Student > Doctoral Student | 2 | 7% |
| Librarian | 1 | 4% |
| Other | 3 | 11% |
| Unknown | 7 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 8 | 29% |
| Psychology | 6 | 21% |
| Medicine and Dentistry | 3 | 11% |
| Neuroscience | 2 | 7% |
| Arts and Humanities | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 6 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2022.
All research outputs
#7,576,061
of 23,103,436 outputs
Outputs from Psychopharmacology
#2,117
of 5,376 outputs
Outputs of similar age
#5,995
of 21,088 outputs
Outputs of similar age from Psychopharmacology
#6
of 16 outputs
Altmetric has tracked 23,103,436 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,376 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 21,088 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.